2015年 第9卷 第1期
《医学前沿（英文）》 >> 2015年 第9卷 第1期 doi: 10.1007/s11684-014-0371-x
Implantation of human umbilical cord mesenchymal stem cells for ischemic stroke: perspectives and challenges
1. Post-Graduate School, Hunan University of Traditional Chinese Medicine, Changsha 410208, China.
2. Department of Neurology, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, Changsha 410007, China
下一篇 上一篇
摘要
Ischemic stroke is a focal cerebral insult that often leads to many adverse neurological complications severely affecting the quality of life. The prevalence of stroke is increasing throughout the world, while the efficacy of current pharmacological therapies remains unclear. As a neuroregenerative therapy, the implantation of human umbilical cord mesenchymal stem cells (hUC-MSCs) has shown great possibility to restore function after stroke. This review article provides an update role of hUC-MSCs implantation in the treatment of ischemic stroke. With the unique “immunosuppressive and immunoprivilege” property, hUC-MSCs are advised to be an important candidate for allogeneic cell treatment. Nevertheless, most of the treatments are still at primary stage and not clinically feasible at the current time. Several uncertain problems, such as culture conditions, allograft rejection, and potential tumorigenicity, are the choke points in this cellular therapy. More preclinical researches and clinical studies are needed before hUC-MSCs implantation can be used as a routinely applied clinical therapy.
京公网安备 11010502051620号
